Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Diabetes. 2012 Jul;61(7):1860-8. doi: 10.2337/db11-1658. Epub 2012 May 14.
Activity of the vascular large conductance Ca(2+)-activated K(+) (BK) channel is tightly regulated by its accessory β(1) subunit (BK-β(1)). Downregulation of BK-β(1) expression in diabetic vessels is associated with upregulation of the forkhead box O subfamily transcription factor-3a (FOXO-3a)-dependent F-box-only protein (FBXO) expression. However, the upstream signaling regulating this process is unclear. Overproduction of reactive oxygen species (ROS) is a common finding in diabetic vasculopathy. We hypothesized that ROS signaling cascade facilitates the FOXO-3a/FBXO-mediated BK-β(1) degradation and leads to diabetic BK channel dysfunction. Using cellular biology, patch clamp, and videomicroscopy techniques, we found that reduced BK-β(1) expression in streptozotocin (STZ)-induced diabetic mouse arteries and in human coronary smooth muscle cells (SMCs) cultured with high glucose was attributable to an increase in protein kinase C (PKC)-β and NADPH oxidase expressions and accompanied by attenuation of Akt phosphorylation and augmentation of atrogin-1 expression. Treatment with ruboxistaurin (a PKCβ inhibitor) or with GW501516 (a peroxisome proliferator-activated receptor δ activator) reduced atrogin-1 expression and restored BK channel-mediated coronary vasodilation in diabetic mice. Our results suggested that oxidative stress inhibited Akt signaling and facilitated the FOXO-3a/FBXO-dependent BK-β(1) degradation in diabetic vessels. Suppression of the FOXO-3a/FBXO pathway prevented vascular BK-β(1) degradation and protected coronary function in diabetes.
血管大电导钙激活钾(BK)通道的活性受到其辅助β(1)亚基(BK-β(1))的紧密调节。糖尿病血管中 BK-β(1)表达的下调与叉头框 O 亚家族转录因子-3a(FOXO-3a)依赖性 F 盒仅蛋白(FBXO)表达的上调有关。然而,调节这一过程的上游信号尚不清楚。活性氧(ROS)的过度产生是糖尿病血管病变的常见发现。我们假设 ROS 信号级联促进 FOXO-3a/FBXO 介导的 BK-β(1)降解,导致糖尿病 BK 通道功能障碍。使用细胞生物学、膜片钳和视频显微镜技术,我们发现链脲佐菌素(STZ)诱导的糖尿病小鼠动脉和高糖培养的人冠状动脉平滑肌细胞(SMC)中 BK-β(1)表达减少归因于蛋白激酶 C(PKC)-β和 NADPH 氧化酶表达的增加,同时伴随着 Akt 磷酸化的减弱和 atrogin-1 表达的增强。用罗格列酮(PKCβ抑制剂)或 GW501516(过氧化物酶体增殖物激活受体δ激活剂)治疗可减少 atrogin-1 的表达,并恢复糖尿病小鼠中 BK 通道介导的冠状动脉舒张。我们的结果表明,氧化应激抑制 Akt 信号并促进糖尿病血管中 FOXO-3a/FBXO 依赖性 BK-β(1)降解。抑制 FOXO-3a/FBXO 途径可防止血管 BK-β(1)降解并保护糖尿病中的冠状动脉功能。